San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor from the weight loss drug sector in February immediately after revealing promising data from the mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the co